{
    "clinical_study": {
        "@rank": "20071", 
        "arm_group": [
            {
                "arm_group_label": "RYGB patients with type 2 diabetes", 
                "description": "Preoperative oral glucose tolerance test with 2 h P-glucose >11.1 mmol/L"
            }, 
            {
                "arm_group_label": "RYGB patients with IGT", 
                "description": "Preoperative oral glucose tolerance test with 2 h p-glucose >7.8 and <11.1 mmol/L"
            }, 
            {
                "arm_group_label": "RYGB patients with NGT", 
                "description": "Preoperative oral glucose tolerance test with 2 h p-Glucose <7.8 mmol/L"
            }
        ], 
        "biospec_descr": {
            "textblock": "Serum and plasma."
        }, 
        "biospec_retention": "Samples Without DNA", 
        "brief_summary": {
            "textblock": "Besides causing weight loss Roux-en-Y gastric bypass (RYGB) has profound effect on glucose\n      metabolism leading to remission of type 2 diabetes early after surgery. However the\n      mechanisms for this improvement remain uncertain. The aim of this study is to investigate\n      the changes in insulin sensitivity and beta-cell function 1 week and 3 months following RYGB\n      using oral and intravenous test."
        }, 
        "brief_title": "Changes in Glucose Metabolism After Roux-en-Y Gastric Bypass", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Type 2 Diabetes", 
            "Obesity"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus, Type 2", 
                "Obesity"
            ]
        }, 
        "detailed_description": {
            "textblock": "Investigators plan to study 24 obese patients already enrolled for Roux-en-y gastric bypass\n      surgery (RYGB). 8 with type 2 diabetes (DM2), 8 with impaired glucose tolerance (IGT) and 8\n      with normal glucose tolerance (NGT) before, within the first week and 3 month after RYGB\n      using a liquid mixed meal test (MMT) and an insulin modified frequently sampled intravenous\n      glucose tolerance test (IM-FSIGT). Furthermore, an oral glucose tolerance test (OGTT) will\n      be performed before and after 3 months. Blood will be sampled in fasting and during the\n      tests measuring plasma glucose, insulin and C-peptid (OGTT, MMT and IM-FSIGT) and GLP-1,\n      glucagon, GIP and GLP-2 (MMT). Beta-cell function will be assessed from the MMT\n      (insulinogenic index - IGI), OGTT (IGI) and the IM-FSIGT (Acute insulin response, AIR) in\n      order to examine whether changes in beta-cell function after RYGB depend on an oral\n      stimulus. Insulin sensitivity will be assessed in fasting (HOMA-IR), during the IM-FSIGT\n      (minimal model: Si) and from MMT/OGTT (Matsuda index). Insulin clearance/hepatic extraction\n      of insulin will be assessed in fasting and during the intravenous and oral test."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  patients eligible for RYGB, Age 18-60 years, BMI 35-60 kg/m2 at time of referral to\n             operation, blood pressure <145/85, C-peptid>700 pmol/l.\n\n        Exclusion Criteria:\n\n          -  Obesity caused by medical treatment for psychiatric disease. Mental retardation.\n             Alcohol or drug abuse. Severe cardiopulmonary disease. History of  peritonitis,\n             ventricular disease, upper gastrointestinal surgery, recurrent oesophagitis or severe\n             complications to general anesthesia. Bad compliance. Treatment with thyroid hormones\n             or antithyroid treatment. Treatment with anorectic medicine later than 3 months prior\n             to surgery. Furthermore prior to surgery each patient has to loose 8 % of bodyweight\n             to reduce the risk of operative complications.\n\n        Before each test day all glucose lowering medication will be paused for an appropriate\n        amount of time depending on the type of medicine."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Morbid obese patients who are already enrolled for Roux-en-y gastric bypass surgery will\n        be invited to participate (investigators do not assign patients to the surgery). 8 with\n        type 2 diabetes, 8 with impaired glucose tolerance and 8 with normal glucose tolerance.\n        Glucose tolerance will be assessed with an oral glucose tolerance test (OGTT) prior to\n        surgery and prior to the other tests. Plasma glucose 120 minutes after OGTT will define\n        glucose tolerance. Normal: < 7,8 mM. Impaired: 7,8 - 11,1 mM. Diabetic: >11,1 mM.\n\n        Subjects are recruited from the outpatient clinic of endocrinology and gastrosurgical\n        clinic at Hvidovre University Hospital."
            }
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01993511", 
            "org_study_id": "SHJNBJ-FX10"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "November 20, 2013", 
        "location": {
            "contact": {
                "email": "kirstine.bojsen-moeller@regionh.dk", 
                "last_name": "Anna Kirstine Bojsen-M\u00f8ller, MD", 
                "phone": "+45 30 25 22 06"
            }, 
            "facility": {
                "address": {
                    "city": "Copenhagen", 
                    "country": "Denmark", 
                    "state": "Hvidovre", 
                    "zip": "2650"
                }, 
                "name": "Hvidovre University Hospital"
            }, 
            "investigator": {
                "last_name": "Anna Kirstine Bojsen-M\u00f8ller, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Denmark"
        }, 
        "number_of_groups": "3", 
        "official_title": "Changes in Glucose Metabolism After Roux-en-Y Gastric Bypass", 
        "other_outcome": [
            {
                "measure": "Change in glucagon and gastrointestinal hormone secretion after RYGB.", 
                "safety_issue": "No", 
                "time_frame": "1 week and 3 months"
            }, 
            {
                "measure": "Change in insulin clearance after RYGB.", 
                "safety_issue": "No", 
                "time_frame": "1 week and 3 months"
            }
        ], 
        "overall_contact": {
            "email": "kirstine.bojsen-moeller@regionh.dk", 
            "last_name": "Anna Kirstine Bojsen-M\u00f8ller, MD", 
            "phone": "+45 30 25 22 06"
        }, 
        "overall_contact_backup": {
            "email": "hjz387@alumni.ku.dk", 
            "last_name": "Christoffer Martinussen, student", 
            "phone": "+45 22 44 55 30"
        }, 
        "overall_official": {
            "affiliation": "Hvidovre University Hospital", 
            "last_name": "Anna Kirstine Bojsen-Moeller, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Denmark: Danish Dataprotection Agency", 
                "Denmark: The Danish National Committee on Biomedical Research Ethics"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Beta-cell function will be assessed with both intravenous tests (acute insulin response to glucose - AIRg) and oral tests (insulinogenic index - IGI).", 
            "measure": "Change in beta-cell function after RYGB.", 
            "safety_issue": "No", 
            "time_frame": "1 week and 3 months."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01993511"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Hvidovre University Hospital", 
            "investigator_full_name": "Anna Kirstine Bojsen-Moeller", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Insulin sensitivity will be assessed in fasting and by intravenous tests (sensitivity index - Si) and oral tests (Matsuda index).", 
            "measure": "Change in insulin sensitivity after RYGB.", 
            "safety_issue": "No", 
            "time_frame": "1 week and 3 months."
        }, 
        "source": "Hvidovre University Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hvidovre University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2010", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "November 2013"
    }
}